Madison Realty Capital Closes $105 Million Acquisition and Modernization Loan for Four Seasons Hotel in Prime Miami Location

NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) — Madison Realty Capital, a vertically integrated real estate private equity firm focused on debt and equity investment strategies, today announced it has provided a $105 million loan to Fort Partners for the acquisition and modernization of the Four Seasons Hotel Miami located at 1435 Brickell Avenue in Brickell, Florida.  The loan was originated from Madison’s income strategy that offers transitional loans to institutional sponsors. In 2019, Madison provided a $210 million loan to Fort Partners for its construction of the Four Seasons Hotel and Private Residences Fort Lauderdale.

“We are pleased to continue our work with Fort Partners, a best-in-class developer with a strong track record in South Florida, and deliver a timely, customized financing solution for this exciting project,” said Josh Zegen, Managing Principal and Co-Founder of Madison Realty Capital. “Fort Partners, in close collaboration with Four Seasons, have put forth a strong plan that will modernize the property focused on enhancing room configurations, pool deck and lobby, and upgrade the food & beverage options by partnering with renowned chefs and restaurateurs.  Moreover, Brickell is an attractive, established neighborhood in Miami that caters to both tourists and business clients given its proximity to South Beach. We look forward to supporting Fort Partners in the future.”

“This is our second large loan with Madison Realty Capital, and again they executed quickly and delivered certainty of execution. Madison offered a highly competitive rate with a flexible structure that will allow us to effectively implement our renovation and repositioning plan for this strategic asset,” said Michael Conaghan, partner with Fort Partners LLC.

The 221-key hotel is part of a 70-story mixed-use tower that includes class-A office space, residential condominiums, an Equinox health club, retail space and a parking garage.  Millennium Partners developed the property in 2003 and Handel Architects led the design. The acquisition marks the fourth Four Seasons property in Fort Partners’ Florida portfolio alongside hotels located in Surfside, Fort Lauderdale, and Palm Beach.

JLL Managing Director Jim Dockerty, Senior Managing Director, Kevin Davis, and Managing Director, Mark Fisher represented Fort Partners in the deal.

 

About Madison Realty Capital 

Madison Realty Capital is a vertically integrated real estate private equity firm that manages approximately $6 billion in total assets on behalf of an institutional global investor base. Since 2004, Madison Realty Capital has completed more than $15 billion in transactions in the U.S. providing reputable borrowers with flexible and highly customized financing solutions, strong underwriting capabilities, and certainty of execution. Headquartered in New York City, with offices in Los Angeles and Miami, the firm has over 60 employees across all real estate investment, development, and property management disciplines. Madison Realty Capital has been frequently named to the Commercial Observer’s prestigious “Power 100” list of New York City real estate players and is consistently cited as a top construction lender, among other industry recognitions. To learn more, follow us on LinkedIn and visit www.madisonrealtycapital.com.

Nathaniel Garnick/Grace Cartwright
Gasthalter & Co.
(212) 257-4170
madisonrealty@gasthalter.com

 

Dante Labs appoints Illumina acclaimed COO Bob Ragusa as Board Member to support the execution of its global integrated precision medicine strategy

  • Bob Ragusa leads Illumina global operations and is a key contributor to Illumina’s growth and global scaling.
  • Dante Labs integrated precision medicine offering leverages the intersection of local lab operations with centralised software and database.
  • Dante Labs mission is to accelerate science to patients to save more lives.

CAMBRIDGE, United Kingdom, July 19, 2021 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, announced today the appointment of Bob Ragusa as a board member. Bob is the Chief Operations Officer of Illumina Inc. (NASDAQ: ILMN), the world leader in sequencing platforms.

Mr. Ragusa stated, “I am very excited to work with Dante to help bridge from improved genomic tools and scientific discovery to positive impact for patients.”

Dante Labs CEO Andrea Riposati stated, “As Illumina customers, we have been amazed by Illumina’s global customer support and operational excellence. Bob is responsible for leading these achievements and for supporting clinical and research labs globally. Bob is a life science rockstar and will help us deploy our global commercial and clinical offering for multi-omics and integrated precision medicine. The entire team at Dante Labs is excited to have his leadership and guidance to support our ambitious growth plan.”

Intersection of Data and Clinical Outcomes

Massive adoption of whole genome sequencing requires changing the paradigm of lab operations and data analysis. Dante Labs has learned the hard way and built the skills to enable massive adoption of whole genome sequencing on a global scale, by working with patients, doctors and companies in 97 countries and generating thousands of clinical and consumer reports every day.

The appointment of Bob Ragusa as a board member has a great strategic fit with the company’s global scaling and growth aspirations. Dante Labs leverages local labs to develop local domain expertise while connecting all local operations in its global network to have superior collective wisdom in every market.

  • Dante Labs integration of software and data with the actual biology in the labs generates unique insights and enables a continuous feedback loop.
  • Dante Labs acquisition of CCG has created a global excellence in precision oncology with the potential of impacting patients worldwide, with a total addressable market of $75 billion.
  • Dante Labs built a stellar team for population genomics and precision medicine.
  • Over 40 countries are actively involved in population genomics programs with many more that can benefit from genome-based preventative medicine for their citizens.
  • Dante Labs serves its customers across 97 countries from clinical laboratories and sequencing centres in the United Kingdom and Italy, with at least two more planned in 2021 to expand its global footprint.

About Dante Labs

Dante Labs is a global genomic data company building and commercialising a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Headquartered in Cambridge, United Kingdom, with a research laboratory in Wolverhampton, Dante Labs supported the UK Government’s urgent requirement to scale-up a high-capacity, highly automated testing solution for Covid-19, including infected patients as well as those with antibodies. Dante Labs was able to deliver by leveraging existing technology that had been developed for whole genome sequencing.

Giorgio Lodi, media@dantelabs.com. +39 0862 191 0671

www.dantelabs.com

Grifols further expands its activity in Africa with agreement to set up an intravenous solutions manufacturing plant in Nigeria

To be constructed by Grifols Engineering, a global standard-bearer in the development and building of advanced production facilities for the healthcare and biotechnology industries

The plant will be operational in 2024 and will produce 5.5 million intravenous solutions (IV) bags yearly for the plant’s owner, Dozie and Dozie’s Pharma Nig Ltd., a leading distributor of healthcare products in Nigeria and neighboring countries

Grifols recently marked a milestone in Africa through a key strategic partnership with the government of Egypt to develop plasma-derived medicines and enhance the region’s self-sufficiency in these treatments

BARCELONA, Spain, July 19, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of technologies and services for hospitals, clinics and compounding centers, today announced it will establish an intravenous (IV) solutions production plant in Nigeria for Dozie and Dozie’s Pharma Nig Ltd., a leading provider of healthcare products in the country and surrounding region.

When completed in 2024 in southeast Nigeria, the manufacturing installation’s initial phase will produce as many as 5.5 million intravenous solutions bags yearly to be used in hospitals and other healthcare institutions in Nigeria and other African countries.

Grifols Engineering, with broad global experience building advanced, specialized production facilities for the healthcare and biotechnology sectors, will design the plant and provide clean rooms and process equipment. Sufficient capacity will be incorporated to enable the doubling of output to meet the expected growth in demand.

“Grifols is extremely pleased to be selected by Dozie and Dozie’s Pharma for a state-of-the-art IV solutions manufacturing plant to enhance healthcare delivery in Nigeria and Western Africa,” said Daniel Fleta, Grifols Chief Industrial Officer.

“This plant is the latest demonstration of our ongoing commitment to provide high-quality medicines and healthcare solutions to meet the growing needs of the region,” stated Chidi Dozie, CEO of Dozie and Dozie’s Pharma Nig Ltd., which currently distributes Grifols plasma-derived therapies.

Grifols strengthened its presence in Africa when in November 2020 it entered into a key strategic alliance with the government of Egypt to develop the local market for plasma-derived therapies, including the opening of 20 plasma centers and the construction of a plasma fractionation plant and a purification and fill-and-finish plant. Africa will benefit from this advanced infrastructure aimed at strengthening regional self-sufficiency in hemoderivatives.

The company has also designed and established a plasma collection center and modular laboratories in Liberia as part of efforts to combat Ebola, and is completing an IV solutions plant it designed and equipped in Morocco.

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with nearly 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2020, Grifols’ economic impact in its core countries of operation was EUR 7.5 billion. The company also generated 140,000 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit www.grifols.com

About Dozie and Dozie’s Pharma Nig Ltd.

With headquarters in Abuja, Nigeria, Dozie and Dozie’s Pharm Nig. Ltd is an award-winning company established in 1990. It was formed with a clear mission of making research-driven specialty medicines available to clients in Nigeria and other parts of Africa. Its focus has been on the importation of medicines in various areas including oncology and immunology, among others. Due to the huge success of this business, the company is progressing towards total exclusivity for these specialised drugs in almost all the tertiary hospitals, corporate hospitals, and the top private clinics and government institutions and agencies. For more information, please visit www.dozieanddoziespharm.com.ng

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, insofar as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

Logo – https://mma.prnewswire.com/media/463444/Grifols_Logo.jpg

 

‫ شركة جريفولز شركة جريفولز Grifols توسع نشاطها في إفريقيا بالاتفاق على إنشاء مصنع لتصنيع المحاليل الوريدية في نيجيريا

–  سيتم بناؤها من قبل شركة جريفولز الهندسية، التي تضطلع بالدور النموذجي العالمي في تطوير وبناء مرافق الإنتاج المتقدمة لصناعات الرعاية الصحية والتكنولوجيا الحيوية

– سيتم تشغيل المصنع في عام 2024 وسينتج 5.5 مليون كيس من المحاليل الوريدية (IV) سنويًا لمالك المصنع، شركة دوزي ودوزي فارما نيج المحدودDozie and Dozie’s Pharma Nig Ltd، الموزع الرائد لمنتجات الرعاية الصحية في نيجيريا والدول المجاورة

– حققت شركة جريفولز مؤخراً منعطفًا جوهرياً في إفريقيا من خلال شراكة إستراتيجية رئيسية مع الحكومة المصرية لتطوير الأدوية المشتقة من البلازما وتعزيز الاكتفاء الذاتي في المنطقة في هذه العلاجات

برشلونة، إسبانيا، 19 يوليو 2021 /PRNewswire/ — شركة جريفولز كود السهم (MCE: GRF, MCE: GRF.P NASDAQ: GRFS)، المنتج العالمي الرائد للأدوية المشتقة من البلازما ومزود للتقنيات والخدمات للمستشفيات، والعيادات، ومراكز التركيبات، أعلنت اليوم أنها ستنشئ مصنعاً لإنتاج المحاليل الوريدية (IV) في نيجيريا لصالح شركة دوزي ودوزي فارما نيج المحدودة، المزود الرائد لمنتجات الرعاية الصحية في الدولة والمنطقة المحيطة بها.

وعند اكتمالها في عام 2024 في جنوب شرق نيجيريا، ستنتج المرحلة الأولية من التصنيع ما يصل إلى 5.5 مليون كيس محاليل وريدية سنوياً لاستخدامها في المستشفيات ومؤسسات الرعاية الصحية الأخرى في نيجيريا ودول أفريقية أخرى.

ستعمل شركة جريفولز الهندسية، التي تتمتع بخبرة عالمية واسعة في بناء مرافق إنتاج متقدمة ومتخصصة لقطاعي الرعاية الصحية والتكنولوجيا الحيوية، على تصميم المصنع وتوفير غرف نظيفة ومعدات معالجة. سيتم دمج السعة الكافية لتمكين مضاعفة الإنتاج لتلبية النمو المتوقع في الطلب.

قال دانيال فليتا، كبير مسؤولي الصناعة في شركة جريفولز: “يسعدنا في جريفولز للغاية أن يتم اختيارنا من قِبل شركة دوزي ودوزي فارما نيج المحدودة لإنشاء مصنع بأحدث صيحة لإنتاج المحاليل الوريدية لتعزيز تقديم الرعاية الصحية في نيجيريا وغرب إفريقيا”.

وصرح تشيدي دوزي، الرئيس التنفيذي لشركة دوزي ودوزي فارما نيج المحدودة، التي توزع حالياً بلازما جريفولز – “هذا المصنع هو أحدث دليل على التزامنا المستمر بتقديم أدوية وحلول رعاية صحية عالية الجودة لتلبية الاحتياجات المتزايدة للمنطقة”.

عززت شركة جريفولز وجودها في إفريقيا عندما دخلت في نوفمبر/تشرين الثاني 2020 في تحالف استراتيجي رئيسي مع الحكومة المصرية لتطوير السوق المحلي للعلاجات المشتقة من البلازما، بما في ذلك افتتاح 20 مركزاً للبلازما وإنشاء مصنع لتجزئة البلازما و مصنع للتنقية والتعبئة والنهائية. سوف تستفيد أفريقيا من هذه البنية التحتية المتقدمة التي تهدف إلى تعزيز الاكتفاء الذاتي الإقليمي من مشتقات الدم.

كما قامت الشركة بتصميم وإنشاء مركز لتجميع البلازما ومختبرات نموذجية في ليبيريا كجزء من الجهود المبذولة لمكافحة فيروس إيبولا، كما أنها تستكمل مصنع للمحاليل الوريدية الذي صممته وجهزته في المغرب.

حول شركة جريفولز

جريفولز هي شركة رعاية صحية عالمية تأسست في برشلونة عام 1909 ملتزمة بتحسين صحة ورفاهية الناس في جميع أنحاء العالم. وتعمل أقسامها الأربعة – العلوم البيولوجية والتشخيصية والمستشفيات والمستلزمات الحيوية – على تطوير وإنتاج وتسويق حلول وخدمات مبتكرة تُباع في أكثر من 100 دولة.

وهي من الرواد في صناعة البلازما، شركة جريفولز تدير شبكة متنامية من مراكز التبرع في جميع أنحاء العالم. إنها تحول البلازما المجمعة إلى أدوية أساسية لعلاج الحالات المزمنة والنادرة وفي بعض الأحيان التي تهدد الحياة. كشركة رائدة معترف بها في طب نقل الدم، تقدم شركة جريفولز أيضاً مجموعة شاملة من الحلول المصممة لتعزيز السلامة بدء من التبرع حتى نقل الدم. بالإضافة إلى ذلك، توفر الشركة الأدوات والمعلومات والخدمات التي تمكن المستشفيات والصيدليات والمتخصصين في الرعاية الصحية من تقديم رعاية طبية متخصصة بكفاءة.

شركة جريفولز، بواسطة ما يقرب من 24000 موظف في أكثر من 30 دولة ومنطقة، ملتزمة بنموذج أعمال مستدام يضع معياراً للابتكار المستمر والجودة والسلامة والقيادة الأخلاقية.

في عام 2020، بلغ التأثير الاقتصادي لشركة جريفولز في البلدان الرئيسية التي تعمل فيها إلى 7.5 مليار يورو. كما وفرت الشركة 140000 وظيفة، بما في ذلك الوظائف غير المباشرة والمعاونة.

أسهم الشركة من الفئة A مدرجة في البورصة الإسبانية، حيث تكون جزءاً من مؤشر Ibex-35 كود السهم (MCE: GRF). تم إدراج أسهم جريفولز غير المصوتة من الفئة B مدرجة في بورصة ماركادو كونتينو، كود السهم (MCE: GRF.P) وفي بورصة ناسداك الأمريكية من خلال إيصالات الإيداع الأمريكية، كود السهم (NASDAQ: GRFS).

لمزيد من المعلومات، يرجى زيارة‎ www.grifols.com

حول شركة دوزي ودوزي فارما نيج المحدودة

 مقرها الرئيسي في أبوجا، نيجيريا، شركة دوزي ودوزي فارما نيج المحدودة  هي شركة حائزة على جوائز وتأسست في عام 1990.  تم تأسيسها بمهمة واضحة تتمثل في إتاحة الأدوية المتخصصة القائمة على الأبحاث للعملاء في نيجيريا وأجزاء أخرى من إفريقيا.  كان تركيزها على استيراد الأدوية في مختلف المجالات بما في ذلك أمراض الأورام والمناعة، وغيرها.  نظراً للنجاح الهائل الذي حققته في هذه الأعمال، تتقدم الشركة نحو الحصرية الكاملة لهذه الأدوية المتخصصة لجميع المستشفيات المتخصصة ومستشفيات الشركات وأهم العيادات الخاصة والمؤسسات والوكالات الحكومية. لمزيد من المعلومات، يرجى زيارة‎ www.dozieanddoziespharm.com.ng

إخلاء المسؤولية القانونية

الحقائق والأرقام الواردة في هذا التقرير والتي لا تشير إلى بيانات تاريخية هي “توقعات وافتراضات مستقبلية”. كلمات وتعابير مثل “يعتقد”، “الأمل”، “توقع”، “نتوقع”، “نعتزم”، “ينبغي”، “نسعى لتحقيق”، “يقدر”، “المستقبل” و استخدام التعبيرات المماثلة، من حيث صلتها بمجموعة جريفولز، لتحديد التوقعات والافتراضات المستقبلية. تعكس هذه التعبيرات الافتراضات، والفرضيات، والتوقعات، والتنبؤات لفريق الإدارة في وقت كتابة هذا التقرير، وهي تخضع لعدد من العوامل التي تعني أن النتائج الفعلية قد تكون مختلفة فعلياً. يمكن أن تتأثر النتائج المستقبلية لمجموعة جريفولز بالأحداث المتعلقة بأنشطتها الخاصة، مثل نقص إمدادات المواد الخام لتصنيع منتجاتها، أو ظهور منتجات منافسة في السوق، أو تغييرات في الإطار التنظيمي للأسواق التي تعمل فيها، وغيرها. في تاريخ إعداد هذا التقرير، اعتمدت مجموعة جريفولز التدابير اللازمة للتخفيف من التأثير المحتمل لهذه الأحداث. لا تقبل شركة جريفولز بأي التزام للإبلاغ علناً أو مراجعة أو تحديث التوقعات أو الافتراضات المستقبلية لتكييفها مع الأحداث أو الظروف اللاحقة لتاريخ كتابة هذا التقرير، باستثناء ما يقتضيه أي تشريع قانوني معمول به صراحة. لا تشكل هذه الوثيقة عرضاً أو دعوة للشراء أو الاكتتاب في الأسهم وفقاً لأحكام التشريع الإسباني التالي: المرسوم التشريعي الملكي 4/2015 بتاريخ 23 أكتوبر/تشرين الأول بالموافقة على إعادة صياغة نص قانون سوق الأوراق المالية؛ والمرسوم الملكي بقانون 5/2005، 11 مارس/آذار و / أو المرسوم الملكي 1310/2005، في 4 نوفمبر/تشرين الثاني، وأي لوائح مستحدثة لهذا التشريع. بالإضافة إلى ذلك، لا يشكل هذا المستند عرضاً للشراء أو البيع أو التبادل، أو طلباً لعرض شراء أو بيع أو تبادل للأوراق المالية، أو طلباً لأي تصويت أو موافقة في أي اختصاص قضائي آخر. لم يتم التحقق من المعلومات الواردة في هذا المستند أو مراجعتها من قبل المدققين الخارجيين لمجموعة جريفولز.

الشعار‎ – https://mma.prnewswire.com/media/463444/Grifols_Logo.jpg

 

 

‫ Ecomondo and Key Energy 2021: التركيز على التحديات الخضراء في القارة الأفريقية وأوروبا.

ريميني RIMINI، إيطاليا، 19 يوليو 2021 /PRNewswire/ — قوة دافعة للأعمال التجارية البيئية ومسرع التحول البيئي: أربعة أيام من تبادل الأعمال والمعرفة مع كبار الخبراء من المفوضية الأوروبية، والمبتكرين، والسلطات الدولية والوطنية، وعالم العلم والجامعة، وصناع القرار، والمستثمرين.اجتمعوا جميعًا في الفترة من 26 إلى29 أكتوبر، في مركز Rimini Expo ريميني إكسبو في إيطاليا، من أجلEcomondo  (الإصدار24Key Energy (الإصدار14 ).أوضح كورادو بيرابوني، الرئيس التنفيذي لـ IEG- – Italian Exhibition Group: “إن هذين العرضين هما من رواد الاقتصاد الأخضر والطاقة المتجددة في حوض منطقة اليورو المتوسط”.إنهم يقدمون المنتجات ويقارنون المشاريع للتحديات الخضراء العالمية التي تمت دعوة كل دولة لحلها، ولا سيما تلك الموجودة في القارة الأفريقية والأوروبية “.

Italian Exhibition Group Logo

 كما تضيف أليساندرا أستولفي، مديرة معرض مجموعة Green & Technology في IEG:“سيتم تمثيل السفارات الأفريقية ل الجزائر ومصر والمغرب وتونس ورواندا و كينيا، على سبيل المثال لا الحصر، في المعارض التجارية، وكذلك الشركات والجمعيات والمشترين من البلدان المذكورة أعلاه ومن أوروبا، لتعزيز أعمالهم. الدراية الفنية وتطوير الشبكات ووضع اللمسات الأخيرة على اتفاقيات الأعمال “.

إلى جانب منطقة المعرض، التي ستشغل جميع مركز المعارض وهي جوهر Ecomondo و Key Energy، سيضم العرضان أيضًا 150 ندوة ومؤتمراً – العديد منها دوليًا وبالإنجليزية – يديرها الأستاذ فابيو فافا و جياني سيلفستريني باسم رؤساء لجانهم العلمية والتقنية المعنيين.الموضوع الرئيسي، حوض البحر الأبيض المتوسط: كجزء من مبادرة BlueMed Pilot وبمشاركة المفوضية الأوروبية، سيوضح الحدث استراتيجيات الإنتاج وإعادة تدوير البلاستيك من أجل بحر نظيف واستعادة النظم البيئية والموائل المتدهورة.وستتناول الأحداث الأخرى موضوع الاقتصاد الحيوي الدائري الذي اقترحه مجلس مهمة صحة التربة والغذاء لضمان أن 75٪ من التربة صحية بحلول عام 2030، بالإضافة إلى https://www.ecomondo.com/eventi/programma/seminari-e-convegni/e17700340/transforming-plastics-litter-into-new-chemicals-opportunities-and-challenges-for-innovative-pyrolysis-plants.htmlورش عملhttps://www.ecomondo.com/eventi/programma/seminari-e-convegni/e17700340/transforming-plastics-litter-into-new-chemicals-opportunities-and-challenges-for-innovative-pyrolysis-plants.html حول تحويل النفايات البلاستيكية.

بالنسبة لـ Key Energy، سيسلط المؤتمر الافتتاحي الضوء على الفرص المتاحة لإيطاليا المرتبطة بـ PNRR، (خطة التعافي الوطني والقدرة على الصمود)، بشأن سياسات الحوافز لانتقال الطاقة وتقييم تأثيرها على نظام الأمة.علاوة على ذلك، سيشمل حدث النمو الأخضر الأفريقي ، بالتعاون مع ITA، وكالة التجارة الإيطالية، ممثلين مؤسسيين ورابطات أفريقية من كينيا ورواندا، بالإضافة إلى الشركات الإيطالية في أفريقيا جنوب الصحراء الكبرى، وسوف يسلط الضوء على الدور المستقبلي لطاقة الرياح في مزيج الطاقة في القارة الأفريقية.موضوع آخر: قطاع الكهرباء، في قلب الإجراءات الأوروبية لإعادة إطلاق الاقتصاد.

جهات الاتصال بالمكتب الصحفي لمجموعة المعارض الإيطالية:

مدير المكتب الصحفي: Marco Forcellini, marco.forcellini@iegexpo.it

منسق المكتب الصحفي الدولي: Silvia Giorgi, silvia.giorgi@iegexpo.it, P. +39-0541-744814

شعار – https://mma.prnewswire.com/media/723307/Italian_Exhibition_Group_Logo.jpg

 

 

 

 

“Maschinen Krieger” to Join OpenSea as NFT Art

YOKOHAMA, Japan, July 19, 2021 /PRNewswire/ — ejworks corporation has announced that digital artwork of Kow Yokoyama, a well-known mechanical designer, is going to be put up on the OpenSea marketplace as a non-fungible token (NFT) on August 6, 2021, for the first time in the world. Yokoyama, one of active Japanese leaders in the mechanical design world, is well known for his masterpiece, “Maschinen Krieger,” and also for mechanical design for Japanese games and movies.https://kyodonewsprwire.jp/prwfile/release/M106711/202107137632/_prw_PI1fl_gwUkB1UD.jpg

Image1: https://kyodonewsprwire.jp/prwfile/release/M106711/202107137632/_prw_PI1fl_gwUkB1UD.jpg

On the occasion of releasing the NFT art, he answered his thoughts on his past and future works in an interview with ejworks corporation.

https://s.ejworks.com/interviewKowYokoyama

In this collection, Yokoyama will release four works of his most famous illustrations of science fiction weapons, including his latest work “SCHWARZER HUND 2021,” from “Maschinen Krieger.”

Event website
https://www.ejworks.com/nft/kowyokoyama/en.html

NFTs and auction details
https://s.ejworks.com/openseaKowYokoyama
Start time: 12:30 (UTC), August 6, 2021
End time: 23:00 (UTC), August 9, 2021

Image2: “snowmanpaint 2018”
https://kyodonewsprwire.jp/prwfile/release/M106711/202107137632/_prw_PI2fl_DF30xbIt.jpg
– Price: $500 & upward
– NFTs produced: 1 unit

Image3: “Big Nut SAFS”
https://kyodonewsprwire.jp/prwfile/release/M106711/202107137632/_prw_PI3fl_jOI1g7Vh.jpg
– Price: $500 & upward
– NFTs produced: 1 unit

Image4: “Operation Super Hammer”
https://kyodonewsprwire.jp/prwfile/release/M106711/202107137632/_prw_PI4fl_1EFF98Zp.jpg
– Price: $500 & upward
– NFTs produced: 1 unit

Image5: “SCHWARZER HUND 2021”
https://kyodonewsprwire.jp/prwfile/release/M106711/202107137632/_prw_PI5fl_5m49z3ip.jpg
– Price: $500 & upward
– NFTs produced: 1 unit

Kow Yokoyama
The most famous Japanese illustrator and modeler, Yokoyama graduated from Musashino Art University’s Department of Japanese Painting in 1980. His representative work is “Maschinen Krieger ZbV3000 (S.F.3.D ORIGINAL).”

Maschinen Krieger ZbV3000
“Maschinen Krieger” is a science fiction mechanical work created in 1980. The series had originally been published in the regular feature series of “SF3D” in a monthly magazine at the time, and it is still in almost the same world as then. Their plastic models that appear in the series have been very popular with fans. It is often abbreviated to “Ma.K.”

About ejworks corporation
ejworks corporation develops, provides, and supports the operation of NFT platforms for artists. The company promotes sales of NFT galleries in its VR space and supports related DX using NFTs for the industry of gaming or publishing, and for leisure or commercial facilities.

Company details: https://kyodonewsprwire.jp/prwfile/release/M106711/202107137632/_prw_PA1fl_3qy4gEn4.pdf

Zoom to Acquire Five9

The combination of Zoom’s robust communications platform with Five9’s intelligent cloud contact center will enable organizations to reimagine the way they engage with their customers

SAN JOSE, Calif. and SAN RAMON, Calif., July 18, 2021 (GLOBE NEWSWIRE) — Zoom Video Communications, Inc. (NASDAQ: ZM) today announced it has entered into a definitive agreement to acquire Five9, Inc. (NASDAQ: FIVN), a leading provider of the intelligent cloud contact center, in an all-stock transaction valued at approximately $14.7 billion. Combining Five9’s Contact Center as a Service (“CCaaS”) solution with Zoom’s broad communications platform will transform how businesses connect with their customers, building the customer engagement platform of the future.

The acquisition is expected to help enhance Zoom’s presence with enterprise customers and allow it to accelerate its long-term growth opportunity by adding the $24 billion contact center market. Five9 is a pioneer of cloud-based contact center software. Its highly-scalable and secure cloud contact center delivers a comprehensive suite of easy-to-use applications that allows management and optimization of customer interactions across many different channels.

“We are continuously looking for ways to enhance our platform, and the addition of Five9 is a natural fit that will deliver even more happiness and value to our customers,” said Eric S. Yuan, Chief Executive Officer and Founder of Zoom. “Zoom is built on a core belief that robust and reliable communications technology enables interactions that build greater empathy and trust, and we believe that holds particularly true for customer engagement. Enterprises communicate with their customers primarily through the contact center, and we believe this acquisition creates a leading customer engagement platform that will help redefine how companies of all sizes connect with their customers. We are thrilled to join forces with the Five9 team, and I look forward to welcoming them to the Zoom family.”

“Businesses spend significant resources annually on their contact centers, but still struggle to deliver a seamless experience for their customers,” said Rowan Trollope, Chief Executive Officer of Five9. “It has always been Five9’s mission to make it easy for businesses to fix that problem and engage with their customers in a more meaningful and efficient way. Joining forces with Zoom will provide Five9’s business customers access to best-of-breed solutions, particularly Zoom Phone, that will enable them to realize more value and deliver real results for their business. This, combined with Zoom’s ‘ease-of use’ philosophy and broad communication portfolio, will truly enable customers to engage via their preferred channel of choice.”

Zoom’s acquisition of Five9 is complementary to the growing popularity of its Zoom Phone offering. Zoom Phone is a modern, cloud phone system that offers a digital alternative to legacy phone offerings, enabling organizations to connect and interact in new and convenient ways to keep businesses moving.

The combination also offers both companies significant cross-selling opportunities to each other’s respective customer bases. As a result of the acquisition, Zoom will play an even greater role in driving the digital future and bringing companies and their customers closer together.

Following the close of the transaction, Five9 will be an operating unit of Zoom and Rowan Trollope will become a President of Zoom and continue as CEO of Five9, reporting to Eric Yuan.

Details on the Proposed Transaction
As part of the agreement, Five9 stockholders will receive 0.5533 shares of Class A common stock of Zoom Video Communications, Inc. for each share of Five9, Inc. Based on the closing share price of Zoom Class A common stock as of July 16, 2021, this represents a per share price for Five9 common stock of $200.28 and an implied transaction value of approximately $14.7 billion.

The Boards of Directors of Zoom and Five9 have approved the transaction. The Board of Directors of Five9 recommends that Five9 stockholders approve the transaction and adopt the merger agreement. The transaction, which is anticipated to close in the first half of calendar year 2022, is subject to approval by Five9 stockholders, the receipt of required regulatory approvals and other customary closing conditions.

Additional details and information about the terms and conditions of the acquisition will be available in current reports on Form 8-K to be filed by Zoom and Five9 with the Securities and Exchange Commission.

Advisors
Goldman Sachs & Co. LLC is serving as exclusive financial advisor and Cooley LLP is serving as legal counsel to Zoom. Qatalyst Partners is serving as exclusive financial advisor and Latham and Watkins LLP is serving as legal counsel to Five9.

Transaction Conference Call Information
Zoom and Five9 will host a Zoom Video Webinar for investors on Monday, July 19, 2021 at 5:30 am Pacific Time / 8:30 am Eastern Time. Investors are invited to join the Zoom Video Webinar by visiting: https://investors.zoom.us/. A replay will be available shortly after the call ends.

About Zoom
Zoom is for you. We help you express ideas, connect to others, and build toward a future limited only by your imagination. Our frictionless communications platform is the only one that started with video as its foundation, and we have set the standard for innovation ever since. That is why we are an intuitive, scalable, and secure choice for individuals, small businesses, and large enterprises alike. Founded in 2011, Zoom is publicly traded (NASDAQ: ZM) and headquartered in San Jose, California. Visit zoom.com and follow @zoom.

About Five9
Five9 is an industry-leading provider of cloud contact center solutions, bringing the power of cloud innovation to more than 2,000 customers worldwide and facilitating billions of customer engagements annually. The Five9 Intelligent Cloud Contact Center provides digital engagement, analytics, workflow automation, workforce optimization, and practical AI to help customers reimagine their customer experience. Designed to be reliable, secure, compliant, and scalable, the Five9 platform helps increase agent and supervisor productivity, connects the contact center to the business, and ultimately deliver tangible business results including increased revenue and enhanced customer trust and loyalty.

Forward-Looking Statements
This communication contains forward-looking information related to Zoom, Five9 and the acquisition of Five9 by Zoom that involves substantial risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements in this communication include, among other things, statements about the potential benefits of the proposed transaction for Zoom, Five9 and their respective customers, Zoom’s plans, objectives, expectations and intentions with respect to the combined company, the size of the opportunity for Zoom in contact centers, the financial condition, results of operations and business of Zoom or Five9, and the anticipated timing of closing of the proposed transaction.

Risks and uncertainties include, among other things, risks related to the ability of Zoom to consummate the proposed transaction on a timely basis or at all; Zoom’s ability to successfully integrate Five9’s operations and personnel; Zoom’s ability to implement its plan, forecasts and other expectations with respect to Five9’s business after the completion of the transaction and realize expected synergies; the satisfaction of the conditions precedent to consummation of the proposed transaction; Zoom’s ability to secure regulatory approvals on the terms expected in a timely manner or at all, especially in light of recent regulatory developments in the United States and elsewhere; the ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; disruption from the transaction making it more difficult to maintain business and operational relationships; any negative effects of the announcement or the consummation of the proposed transaction on the market price of Zoom’s Class A common stock or on Zoom’s operating results; the impact of significant transaction costs and unknown liabilities on Zoom’s operating results; the risk of litigation and/or regulatory actions related to the proposed transaction; the exertion of management’s time and Zoom’s resources, and other expenses incurred in connection with any regulatory or governmental consents or approvals for the transaction; the possibility that competing offers will be made to acquire Five9; the effect of the announcement or pendency of the transaction on Zoom and Five9’s business relationships, operating results, and business generally; the impact of the COVID-19 pandemic and related public health measures on Zoom and Five9’s businesses and general economic conditions; the impact of geopolitical events; Zoom’s service performance and security, including the resources and costs required to avoid unanticipated downtime and prevent, detect and remediate potential security breaches; cyberattacks and security vulnerabilities that could lead to reduced revenue, increased costs, liability claims, or harm to Zoom’s reputation or competitive position; excessive outages and disruptions to Zoom’s online services if Zoom fails to maintain an adequate operations infrastructure; competitive factors, including new market entrants and changes in the competitive environment and increased competition; customer demand for Zoom’s products and services; Zoom and Five9’s ability to attract, integrate and retain qualified personnel; Zoom’s ability to protect its intellectual property rights and develop its brand; Zoom’s ability to develop new services and product features; Zoom’s operating results and cash flow; the impact of the transaction on Zoom’s strategy of acquiring or making investments in complementary businesses, joint ventures, services, technologies and intellectual property rights; changes in tax and other laws, regulations, rates and policies; and the impact of new accounting pronouncements.

These risks, as well as other risks related to the proposed transaction, will be described in the registration statement on Form S-4 and proxy statement/prospectus that will be filed with the SEC in connection with the proposed transaction. While the list of factors presented here is, and the list of factors to be presented in the registration statement on Form S-4 are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. For additional information about other factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Zoom’s and Five9’s respective periodic reports and other filings with the SEC, including the risk factors identified in Zoom’s and Five9’s most recent Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K.

The forward-looking statements included in this communication are made only as of the date hereof. Zoom assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

Additional Information and Where to Find It

In connection with the proposed merger, Zoom intends to file with the SEC a registration statement on Form S-4, which will include a document that serves as a prospectus of Zoom and a proxy statement of Five9 (the “proxy statement/prospectus”). After the registration statement has been declared effective by the SEC, the proxy statement/prospectus will be delivered to stockholders of Five9. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, SECURITY HOLDERS OF ZOOM AND FIVE9 ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND OTHER DOCUMENTS RELATING TO THE MERGER THAT WILL BE FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. Investors and security holders will be able to obtain copies of the proxy statement/prospectus (when available) and other documents filed by Zoom and Five9 with the SEC, without charge, through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Zoom will be available free of charge under the SEC Filings heading of the Investor Relations section of Zoom’s website at https://investors.Zoom.us/. Copies of the documents filed with the SEC by Five9 will be available free of charge under the Financials & Filings heading of the Investor Relations section of Five9’s website at https://investors.five9.com/.

Participants in the Solicitation

Zoom and Five9 and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about Zoom’s directors and executive officers is set forth in Zoom’s Form 10-K for the year ended January 31, 2021 and the proxy statement for Zoom’s 2021 Annual Meeting of Stockholders, which were filed with the SEC on March 18, 2021 and May 5, 2021, respectively. Information about Five9’s directors and executive officers is set forth in Five9’s Form 10-K for the year ended December 31, 2020 and the proxy statement for Five9’s 2021 Annual Meeting of Stockholders, which were filed with the SEC on March 1, 2021 and March 29, 2021, respectively. Stockholders may obtain additional information regarding the interests of such participants by reading the registration statement and the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when they become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions.

No Offer or Solicitation

This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Zoom Press Relations
Colleen Rodriguez
Global Media Relations Lead
press@zoom.us

Zoom Investor Relations
Tom McCallum
Head of Investor Relations
investors@zoom.us

Five9 Press Relations
Allison Wilson
352-502-9539
allison.wilson@five9.com

Five9 Investor Relations
Barry Zwarenstein
Chief Financial Officer
925-201-2000 ext. 5959
ir@five9.com

The Blueshirt Group for Five9, Inc.
Lisa Laukkanen
415-217-4967
lisa@blueshirtgroup.com

‫شركة سيجين تطرح اختبار اكتشاف متحورات سارز – كوف -2 الجديد الذي يمكنه فحص ستة متحورات فيروسات بما في ذلك دلتا ودلتا بلاس

  • أطلقت شركة سيجين (Seegene) اختبار PCR متعدد الأهداف جديدا قادرا على فحص ستة متحورات  فيروس  سارز – كوف 2 بما في ذلك متحورا دلتا ودلتا بلاس اللذان يُعزى إليهما الارتفاع الأخير في حالات الإصابة العالمية بكوفيد-19.
  • مجموعة أدوات الكشف عن المتحورات الحاصلة على علامة CE-IVD للتمييز بين 10 متحورات رئيسية لـكوفيد-19 بما في ذلك “ألفا”، “بيتا” و”أبسيلون” بالإضافة إلى “دلتا”، عند استخدامها لى جانب مجموعة أدوات الكشف عن المتحورات الأولى للشركة والتي تم إطلاقها مسبقًا في شهر آذار/مارس الماضي.

سيئول، كوريا الجنوبية، 19 تموز/يوليو 2021 / PRNewswire / — أعلنت شركة التكنولوجيا الحيوية الرائدة في كوريا الجنوبية سيجين (KQ 096530) عن إطلاق اختبار تشخيص للمتحورات الجديدة لفيروس سارز-كوف 2 قادر على فحص متحورات الفيروس التي اكتشفت حديثًا بما في ذلك متحورا دلتا ودلتا بلاس اللذان أصبحا النسخة السائدة للفيروس المنتشر حول العالم حاليا.

Logo

أعلنت شركة سيجين في 30 يونيو أنها حصلت على علامة CE-IVD لفحص Allplex ™ SARS-CoV-2 Variants II، وهي مجموعة جديدة من مجموعات الكشف عن متحورات الفيروس من الشركة القادرة على اكتشاف الطفرات الجينية الرئيسية لمتحورات فيروس سارز-كوف-2  مثل L452R، وW152C، وK417T، وK417N. ففي تفاعل واحد، تحدد مجموعة تشخيص المتحورات ما مجموعه ستة متحورات من كوفيد-19 معروف أنها نشأت في الهند مثل دلتا، دلتا بلاس، كابا وغاما (البرازيل) و بيتا (جنوب إفريقيا) وإبسيلون (كاليفورنيا). وفي حين أن عدد الإصابات الجديدة اليومية بالفيروس ينمو بصورة كبيرة، من المتوقع أن يلعب إطلاق الاختبار الجديد دورًا أساسيًا في مراقبة انتشار متحوري دلتا ودلتا بلاس اللذين يعزى إليهما إلى حد كبير الجزء الأكبر من الإصابات الجديدة.

في وقت سابق من هذا العام، صنفت منظمة الصحة العالمية متحور دلتا على أنه “متحور مثير للقلق” حيث من المتوقع أن يتفوق هذا المتحور بسرعة على المتحورات الأخرى للفيروس. أيضًا، أثار ظهور طفرة جديدة على بروتين سبايك في متحور دلتا المعروف باسم K417N  قلقًا عالميًا، حيث من المعروف أنه أكثر عدوى من متحور دلتا ويظهر مقاومة للقاح. وأصبحت هذه المتحورات شديدة العدوى مؤخرًا تمثل تهديدًا عالميًا.  في دول مثل المملكة المتحدة وإندونيسيا، تعتبر دلتا السلالة السائدة المسؤولة عن حوالي 90٪ من حالات الإصابة الجديدة.  أيضًا، في بلدان أخرى مثل الولايات المتحدة، على الرغم من أن المتحور يشكل حوالي 20٪ فقط من الإصابات، يبدو أن العدد يتضاعف كل أسبوعين.

في ظل هذه الظروف، يحظى طرح اختبار Allplex ™ SARS-CoV-2 Variants II Assay باهتمام كبير في جميع أنحاء العالم حيث يمكن لمجموعة الاختبار هذه الكشف عن متحوري دلتا ودلتا بلاس بالإضافة إلى متحورات كوفيد-19 الرئيسية الأخرى. وقالت سيجين أيضًا إنها طورت بنجاح اختبارات تشخيصية للاستخدام البحثي فقط، Allplex™ SARS-CoV-2/P681R Assay لاستهداف متحوري دلتا ودلتا بلاس بدقة. ووفقًا للشركة، فإن الاستخدام المتزامن للفحصين سيسمح للباحثين بالتمييز بدقة بين متحوري دلتا ودلتا بلاس من الطفرات الجينية الأخرى.

على الرغم من أن العديد من البلدان تسرع في عملية التطعيم، فإن تحالف غافي،وهو التحالف العالمي للقاحات يشدد على أهمية فحوص الكشف عن الفيروس، قائلاً إنه تم تحديد متحوري  دلتا ودلتا بلاس أثناء الفحص الروتيني. وفقًا لسيجين، فإن الجمع بين استخدام اثنين من الاختبارات بما في ذلك اختبار Allplex ™ SARS-CoV-2 Variants II وAllplex ™ SARS-CoV-2 Variants I Assay  يمكنه فحص جميع متحورات كوفيد-19 الحالية تقريبًا. نظرًا لأن الاختبارين يمكنهما اكتشاف متحورات متعددة في اختبار واحد، فإن استخدامهما يبسط أيضًا عملية الاختبار التقليدية التي تتطلب اختبارًا ثانويًا لتحديد المتحورات الجديدة. وفي مثل هذا السياق، من المتوقع أن تصبح مجموعة أدوات الفحص المتعددة الأهداف من سيجين “معيارًا ذهبيًا” جديدًا، ما يساعد على منع حدوث أوبئة جديدة.

وقال مين تشيول لي، رئيس قسم التكنولوجيا في سيجين: “إن قابلية الانتقال المتزايدة للفيروس، وفترة الحضانة القصيرة، والانخفاض المحتمل في فعالية اللقاحات هي خصائص متحورات دلتا ودلتا بلاس.” وأضاف: “أعلم أن هناك حاليًا الكثير من القلق بشأن متحورات دلتا. بينما يحذر الخبراء ومنظمة الصحة العالمية الجمهور والحكومات للبقاء متيقظين، أعتقد أن آخر اختبارين للتشخيص لدينا سيلعبان دورًا رئيسيًا في الكشف المبكر عن فيروسات مختلفة ويساعدان في منع انتشار المزيد من فيروس سارزكوف2.”

شركة سيجين
جيسيكا جيونغ بارك
رقم الهاتف: 6164-2240-2-82+
بريد إلكتروني: jypark2@seegene.com

للتواصل الإعلامي في الولايات المتحدة الأميركية:
كريستين شيفر
بريد إلكتروني: kschaeffer@cglife.com

الشعار – https://mma.prnewswire.com/media/1357790/Seegene_logo_Logo.jpg

 

 

QOC completes vaccination program for international atheletes ahead of Tokyo 2020 Olympics

DOHA-The Qatar Olympic Committee has completed its vaccination program for athletes who were unable to be vaccinated in their home countries in advance of travelling to Japan for the Tokyo 2020 Olympic Games.

After a group of countries joined this great initiative, the QOC agreed jointly with the IOC, Pfizer-BioNTech and Qatar Airways to provide vaccinations

To this end, last week, the QOC completed all vaccine doses for participants of the countries who joined the initiative. Participants arrived at Hamad International Airport and stayed at Doha’s training camp. The QOC provided all necessary measures required for the athletes and delegations in cooperation with Qatar’s Ministry of Interior, Ministry of Public Health and Hamad International Airport.

The QOC is proud to cooperate with the IOC in pushing the Olympic Movement forward amid this COVID-19 and supporting the Tokyo 2020 organizers to host a safe and successful Games.

Source: Qatar Olympic Committee

Ayoub El-Idrissi arrives in Tokyo

Tokyo-Qatar’s judoka Ayoub El-Idrissi arrived in Tokyo on Monday to participate in Tokyo 2020 Olympics, which will be held in Japan between July 23 and August 8.

Ayoub Al Idrissi secured his spot at the Olympics well after collecting 699 points thanks to his impressive run in 2020 and 2021, especially in the recent Grand Slam tournaments in Georgia, Turkey and Russia, and the World Championships in Hungary in last June.

For his part, Qatar’s shooter Mohammed Al Rumaihi has underlined his readiness to battle for top honors at the Olympic Games.

The trap shooter will begin his campaign at Tokyo Olympics on July 28 with qualifications while finals will be staged on July 29.

Al Rumaihi had won an Olympic quota place at the 2019 Asian Championships in Doha.

Rower Tala Abujbara, who arrived on Saturday, have continued her finals preparations for the games for the second day.

After their arrival in Tokyo on Sunday, Qatar’s volleyball duo of Cherif Younousse and Ahmed Tijan had their first practice session in Tokyo on Monday.

The preliminary rounds of beach volleyball event will begin next Saturday while the finals will be held on August 07.

With only few days to go for the start of the 2020 Olympic Games, Qatar’s athletics stars stepped up their preparations for the games at their training camp in Takasaki.

Qatar’s Bashayer al-Mnawari will be the first Qatari athlete to hit the track at Women’s 100m event.

Started out as a triple jump athlete, then found herself in short distance running, Almanwari is a West Asian champion in 2013 and 5-time GCC champion.

In Monday morning, Qatar’s media delegation chief, Abdulhadi Al Sahli attended the Tokyo 2020 Olympic Games’ media meeting hosted by the Games organizing committee, at which logistics and media issues of the games, including transport, social media platforms, COVID-19 preventive measures and media personnel’s accreditations were discussed and approved.

Source: Qatar Olympic Committee